Zelluna ASA (OSL:ZLNA)
Norway
· Delayed Price · Currency is NOK 16.13
+0.54 (3.44%)
Mar 9, 2026, 4:14 PM CET
Zelluna ASA Company Description
Zelluna ASA develops T-cell receptor (TCR) cellular immunotherapy products for the treatment of solid cancers.
The company has a clinical partnership with Medpace Holdings, Inc. to support the clinical trial of ZI-MA4-1 (ZIMA-101).
The company was founded in 2016 and is based in Oslo, Norway.
Zelluna ASA
| Country | Norway |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Namir Hassan |
Contact Details
Address: Ullernchausséen 64 Oslo, 0379 Norway | |
| Phone | 47 22 84 00 80 |
| Website | zelluna.com |
Stock Details
| Ticker Symbol | ZLNA |
| Exchange | Oslo Børs |
| Fiscal Year | January - December |
| Reporting Currency | NOK |
| ISIN Number | NO0013524942 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Namir Hassan Ph.D. | Chief Executive Officer |
| Oivind Foss Ph.D. | Head of Clinical Operations |
| Jens Egil Torbjorn Bjorheim M.D., Ph.D. | Chief Medical Officer |
| Orla Mc Callion | Head of Regulatory Affairs and QA |
| Anders Tuv | Co-Founder and Chairman |
| Hans Ivar Robinson | Co-Founder and Non Executive Director |
| Geir Christian Melen MSc | Chief Financial Officer |
| Anders Holm Ph.D. | Chief Operating Officer and Head of Business Development |
| Emilie Gauthy Ph.D. | Chief Technology Officer |
| Luise Weigand Ph.D. | Chief Scientific Officer |